So you can see from the initial response I made to
Post# of 148187
(Total Views: 580)
Posted On: 05/08/2022 6:37:37 AM
Re: USS JOHNSTON #122963
So you can see from the initial response I made to you respecting NASH 700, it is not CytoDyn's intention to proceed with NASH without a partner.
Second, I'm speaking from my understanding on LL, it would be very difficult to find any substance that will dilute LL's effectiveness. Not even HIV can defeat LL in binding to CCR5. We defeat HIV because be bind to CCR5 with tremendous affinity and it takes over a month for that affinity to start breaking loose.
Lastly, from here: https://www.biospace.com/article/madrigal-pha...esmetirom/
Madrigal’s resmetirom is designed to activate the β-receptor in hepatocytes, which plays a central role in liver function, including the breakdown of liver fat and control of the level of normal, healthy mitochondria NASH patients have reduced levels of thyroid hormone activity in the liver due to the inflamed state of the liver that causes degradation of thyroid hormone.
Madrigal's drug also reduces cholesterol and it seems like it has a beneficial effect on atherosclerosis. I believe LL could help reduce cholesterol secondarily by improving liver function. I believe LL could help reduce atherosclerosis primarily because atherosclerosis is produced by an inflammatory process combining calcium and cholesterol and LL is anti-inflammatory.
Point is, LL won't interfere with Resmetirom and Resmetirom won't interfere with LL. Together the outcome would be even better than what LL could achieve on its own.
Yes, even in 350mg dosage we had a p value of 0.02 which was significant. 80% had 50ms and 50% had 80ms reduction in CT1 which reveals a massive reduction in fatty liver. 40ms is what they look for in Biopsy. 80% had 50ms. Even in 350mg, we reached this. How much will we reach in 700mg? 100ms on average? 150ms average? 4 times better than what Biopsy can measure? Lets wait and see.
But we can not do this alone. But, if you're thinking to use a partner like Samsung, yes, I would agree. We just need the financing for phase iii trial and we can do this one alone because we are far better than anyone. Madrigal's drug does not reduce Fibrosis. Madrigal's measuring system does not use biopsy and since they don't effect fibrosis, I don't believe they would achieve any reduction in CT1.
Second, I'm speaking from my understanding on LL, it would be very difficult to find any substance that will dilute LL's effectiveness. Not even HIV can defeat LL in binding to CCR5. We defeat HIV because be bind to CCR5 with tremendous affinity and it takes over a month for that affinity to start breaking loose.
Lastly, from here: https://www.biospace.com/article/madrigal-pha...esmetirom/
Madrigal’s resmetirom is designed to activate the β-receptor in hepatocytes, which plays a central role in liver function, including the breakdown of liver fat and control of the level of normal, healthy mitochondria NASH patients have reduced levels of thyroid hormone activity in the liver due to the inflamed state of the liver that causes degradation of thyroid hormone.
Madrigal's drug also reduces cholesterol and it seems like it has a beneficial effect on atherosclerosis. I believe LL could help reduce cholesterol secondarily by improving liver function. I believe LL could help reduce atherosclerosis primarily because atherosclerosis is produced by an inflammatory process combining calcium and cholesterol and LL is anti-inflammatory.
Point is, LL won't interfere with Resmetirom and Resmetirom won't interfere with LL. Together the outcome would be even better than what LL could achieve on its own.
Yes, even in 350mg dosage we had a p value of 0.02 which was significant. 80% had 50ms and 50% had 80ms reduction in CT1 which reveals a massive reduction in fatty liver. 40ms is what they look for in Biopsy. 80% had 50ms. Even in 350mg, we reached this. How much will we reach in 700mg? 100ms on average? 150ms average? 4 times better than what Biopsy can measure? Lets wait and see.
But we can not do this alone. But, if you're thinking to use a partner like Samsung, yes, I would agree. We just need the financing for phase iii trial and we can do this one alone because we are far better than anyone. Madrigal's drug does not reduce Fibrosis. Madrigal's measuring system does not use biopsy and since they don't effect fibrosis, I don't believe they would achieve any reduction in CT1.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼